Related Experiment Video
Updated: Feb 14, 2026

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling
Published on: December 18, 2017
Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
Hamid Sayar1, Yan Liu2, Rui Gao2
1Indiana University Melvin and Bren Simon Cancer Center, Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract:
Co-occurrence of Flt3ITD and TET2 mutations provoke an animal model of AML by epigenetic repression of Wnt pathway antagonists, including RUNX3, and by hyperexpression of ID1, encoding Wnt agonist. These affect HOXA over-expression and treatment resistance. A comparable epigenetic phenotype was identified among adult AML patients needing novel intervention. We chose combinations of targeted agents acting on distinct effectors, at the levels of both signal transduction and chromatin remodeling, in relapsed/refractory AML's, including Flt3ITD+ve, described with a signature of repressed tumor suppressor genes, involving Wnt antagonist RUNX3, occurring along with ID1 and HOXA over-expressions. We tracked patient response to combination of Flt3/Raf inhibitor, Sorafenib, and Vorinostat, pan-histone deacetylase inhibitor, without or with added Bortezomib, in consecutive phase I trials. A striking association of rapid objective remissions (near-complete, complete responses) was noted to accompany induced early pharmacodynamic changes within patient blasts in situ, involving these effectors, significantly linking RUNX3/Wnt antagonist de-repression (80%) and ID1 downregulation (85%), to a response, also preceded by profound HOXA9 repression. Response occurred in context of concurrent TET2 mutation/hypomorphy and Flt3ITD+ve mutation (83% of complete responses). Addition of Bortezomib to the combination was vital to attainment of complete response in Flt3ITD+ve cases exhibiting such Wnt pathway dysregulation.
Insights
The combination of targeted agents, including Sorafenib and Vorinostat, shows promise in treating relapsed/refractory acute myeloid leukemia (AML) by reversing epigenetic changes. Bortezomib addition improved complete response rates in specific AML subtypes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) with FLT3-ITD and TET2 mutations exhibits a distinct epigenetic phenotype.
- This phenotype involves Wnt pathway dysregulation, including repression of antagonists like RUNX3 and hyperexpression of agonists like ID1.
- This epigenetic signature is also observed in adult AML patients, indicating a need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of targeted agent combinations in relapsed/refractory AML with a specific epigenetic profile.
- To evaluate the impact of Sorafenib (FLT3/Raf inhibitor) and Vorinostat (pan-histone deacetylase inhibitor), with or without Bortezomib, on patient response.
- To correlate early pharmacodynamic changes with clinical outcomes in AML patients.
Main Methods:
- Phase I clinical trials were conducted on relapsed/refractory AML patients, including those with FLT3-ITD mutations.
- Patients received a combination of Sorafenib and Vorinostat, with some also receiving Bortezomib.
- Pharmacodynamic analyses were performed on patient blasts to assess changes in key genes (RUNX3, ID1, HOXA9) and Wnt pathway activity.
Main Results:
- Rapid objective remissions were observed, strongly associated with early pharmacodynamic changes.
- De-repression of RUNX3 (80%) and downregulation of ID1 (85%) were significantly linked to treatment response.
- Profound HOXA9 repression preceded objective responses, particularly in patients with concurrent TET2 and FLT3-ITD mutations.
- Addition of Bortezomib was crucial for achieving complete responses in FLT3-ITD positive AML with Wnt pathway dysregulation.
Conclusions:
- Combination therapy with Sorafenib and Vorinostat can reverse the aberrant epigenetic phenotype in AML.
- Targeting both signal transduction and chromatin remodeling pathways offers a promising strategy for relapsed/refractory AML.
- Bortezomib plays a vital role in achieving complete remission in specific FLT3-ITD positive AML cases.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Subviral Agents
Other Glycolytic Pathways
Respiration Pathways

